DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Natural Cycle In Vitro Fertilization

Information source: Reproductive Medicine Associates of New Jersey
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Natural Cycle in Vitro Fertilization (IVF)

Intervention: Uterine Aspiration and Endometrial Biopsy/Embryo Biopsy (Procedure); Leuprolide Acetate (Drug); Human Chorionic Gonadotropin (hCG) (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Reproductive Medicine Associates of New Jersey

Official(s) and/or principal investigator(s):
Richard T Scott, M.D., HCLD, Principal Investigator, Affiliation: Reproductive Medicine Associates of New Jersey

Overall contact:
Christine V Reda, BSN, RN, Phone: 973-656-2841, Email: clinicalresearchteam@rmanj.com

Summary

Natural IVF study patients will undergo an IVF cycle with trigger shots of Lupron & hCG. Patients will not be given any other stimulating medications during the cycle. They will have 2 uterine aspirations and an endometrial biopsy at designated times. The first uterine aspiration will be randomized to one of four days (day before retrieval, day of retrieval, day after retrieval or 2 days after retrieval). The second uterine aspiration and endometrial biopsy will be performed 6 days after retrieval. Any embryo(s) obtained will be biopsied for Comprehensive Chromosome Screening (CCS) and frozen for use in a subsequent thaw cycle.

Clinical Details

Official title: Natural Cycle In Vitro Fertilization

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Endometrial Changes

Secondary outcome: Aneuploidy Rates

Eligibility

Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Ovulatory cycles every 39 days or less (natural cycle IVF cannot be performed in

someone who does not have cycles)

- Must be RMANJ patient and have completed all diagnostic screening at one of our RMANJ

locations. All diagnostic screening is NOT covered under the study and must be completed prior to being allowed to start the study cycle. Exclusion Criteria:

- Prior enrollment/attempt in this study

- Requirement for surgical sperm extraction

- Inability to assess ovaries via transvaginal ultrasound

- Inability to tolerate vaginal examination

Locations and Contacts

Christine V Reda, BSN, RN, Phone: 973-656-2841, Email: clinicalresearchteam@rmanj.com

Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey 07920, United States; Recruiting
Christine V Reda, BSN, RN, Phone: 973-656-2841, Email: clinicalresearchteam@rmanj.com
Talia Metzgar, RN, Phone: 973-656-2841, Email: clinicalresearchteam@rmanj.com
Richard T Scott, M.D., HCLD, Principal Investigator
Additional Information

Reproductive Medicine Associates of New Jersey

Starting date: April 2013
Last updated: March 25, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017